DE602004015810D1 - Substituierte isochinolinderivate und anwendungsverfahren - Google Patents
Substituierte isochinolinderivate und anwendungsverfahrenInfo
- Publication number
- DE602004015810D1 DE602004015810D1 DE602004015810T DE602004015810T DE602004015810D1 DE 602004015810 D1 DE602004015810 D1 DE 602004015810D1 DE 602004015810 T DE602004015810 T DE 602004015810T DE 602004015810 T DE602004015810 T DE 602004015810T DE 602004015810 D1 DE602004015810 D1 DE 602004015810D1
- Authority
- DE
- Germany
- Prior art keywords
- diseases
- substituted
- compounds
- prophylaxis
- processes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000002537 isoquinolines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49787703P | 2003-08-25 | 2003-08-25 | |
| US10/926,218 US7390820B2 (en) | 2003-08-25 | 2004-08-24 | Substituted quinolinone derivatives and methods of use |
| PCT/US2004/027762 WO2005021533A1 (en) | 2003-08-25 | 2004-08-25 | Substituted isoquinoline derivatives and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004015810D1 true DE602004015810D1 (de) | 2008-09-25 |
Family
ID=34221528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004015810T Expired - Lifetime DE602004015810D1 (de) | 2003-08-25 | 2004-08-25 | Substituierte isochinolinderivate und anwendungsverfahren |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7390820B2 (de) |
| EP (1) | EP1664023B1 (de) |
| JP (1) | JP2007504148A (de) |
| AT (1) | ATE404552T1 (de) |
| AU (1) | AU2004269020A1 (de) |
| CA (1) | CA2534571A1 (de) |
| DE (1) | DE602004015810D1 (de) |
| ES (1) | ES2310758T3 (de) |
| MX (1) | MXPA06002014A (de) |
| WO (1) | WO2005021533A1 (de) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
| EP1885369B1 (de) | 2005-05-04 | 2015-09-23 | Evotec AG | Fusionierte heterozyklische verbindungen und zusammensetzungen sowie anwendungen davon |
| EP1921065B1 (de) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridonderivat |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| WO2007093366A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
| EA019961B1 (ru) | 2006-04-04 | 2014-07-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Антагонисты киназы |
| CN101506171A (zh) * | 2006-06-19 | 2009-08-12 | 阿斯利康(瑞典)有限公司 | 作为细胞因子介导的疾病的抑制剂的异喹啉衍生物及其用途 |
| EP2121654A1 (de) * | 2007-01-10 | 2009-11-25 | Albany Molecular Research, Inc. | 5-pyridinon-substituierte indazole |
| ES2576643T3 (es) * | 2007-03-09 | 2016-07-08 | Second Genome, Inc. | Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos |
| KR20100044225A (ko) * | 2007-07-21 | 2010-04-29 | 알바니 몰레큘라 리써치, 인크. | 5-피리디논 치환된 인다졸 |
| US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP5869222B2 (ja) | 2008-01-04 | 2016-02-24 | インテリカイン， エルエルシー | 特定の化学的実体、組成物および方法 |
| WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| EP2252293B1 (de) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinasehemmer und verwendungsverfahren |
| US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| ES2570429T3 (es) | 2008-10-16 | 2016-05-18 | Univ California | Inhibidores de heteroaril quinasa de anillo condensado |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| EP2373646A4 (de) * | 2008-12-16 | 2012-07-18 | Sirtris Pharmaceuticals Inc | Phthalazinon und verwandte analoga als sirtuin-modulatoren |
| EP2427195B1 (de) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclische verbindungen und ihre verwendung |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| UA115767C2 (uk) | 2011-01-10 | 2017-12-26 | Інфініті Фармасьютікалз, Інк. | Способи отримання ізохінолінонів і тверді форми ізохінолінонів |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| AU2012341028C1 (en) | 2011-09-02 | 2017-10-19 | Mount Sinai School Of Medicine | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| MX2015003874A (es) | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| AU2014253798C1 (en) | 2013-04-19 | 2019-02-07 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN105793255B (zh) | 2013-10-04 | 2018-11-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2015231413B2 (en) | 2014-03-19 | 2020-04-23 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR20190033526A (ko) | 2016-06-24 | 2019-03-29 | 인피니티 파마슈티칼스, 인코포레이티드 | 병용 요법 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3788047B1 (de) | 2018-05-04 | 2024-09-04 | Incyte Corporation | Feste formen eines fgfr-inhibitors und verfahren zur herstellung davon |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI825637B (zh) * | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| EP4323405A1 (de) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Kombinationstherapie mit einem fgfr-inhibitor und einem auf nectin-4 abzielenden mittel |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| WO2024108131A1 (en) * | 2022-11-18 | 2024-05-23 | Soley Therapeutics, Inc. | Phthalazinone based modulators for the treatment of disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2874156A (en) * | 1959-02-17 | Substituted l | ||
| DE1029379B (de) | 1955-07-15 | 1958-05-08 | Hoechst Ag | Verfahren zur Darstellung von oxy- bzw. aminogruppenhaltigen 2, 3-Diphenyl-1, 4-dioxo-tetra-hydrophthalazinen |
| DE956044C (de) | 1954-08-08 | 1957-01-10 | Hoechst Ag | Verfahren zur Herstellung von oxy- bzw. aminogruppenhaltigen 2, 3-Diphenyl-1, 4-dioxo-tetrahydrophthalazinen |
| AU6777896A (en) * | 1995-08-25 | 1997-03-19 | E.I. Du Pont De Nemours And Company | Bicyclic herbicides |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
-
2004
- 2004-08-24 US US10/926,218 patent/US7390820B2/en active Active
- 2004-08-25 EP EP04782276A patent/EP1664023B1/de not_active Expired - Lifetime
- 2004-08-25 CA CA002534571A patent/CA2534571A1/en not_active Abandoned
- 2004-08-25 AT AT04782276T patent/ATE404552T1/de not_active IP Right Cessation
- 2004-08-25 JP JP2006524851A patent/JP2007504148A/ja not_active Withdrawn
- 2004-08-25 AU AU2004269020A patent/AU2004269020A1/en not_active Abandoned
- 2004-08-25 MX MXPA06002014A patent/MXPA06002014A/es unknown
- 2004-08-25 DE DE602004015810T patent/DE602004015810D1/de not_active Expired - Lifetime
- 2004-08-25 ES ES04782276T patent/ES2310758T3/es not_active Expired - Lifetime
- 2004-08-25 WO PCT/US2004/027762 patent/WO2005021533A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005021533A1 (en) | 2005-03-10 |
| ES2310758T3 (es) | 2009-01-16 |
| AU2004269020A1 (en) | 2005-03-10 |
| EP1664023A1 (de) | 2006-06-07 |
| US7390820B2 (en) | 2008-06-24 |
| ATE404552T1 (de) | 2008-08-15 |
| MXPA06002014A (es) | 2006-05-17 |
| US20050049253A1 (en) | 2005-03-03 |
| EP1664023B1 (de) | 2008-08-13 |
| CA2534571A1 (en) | 2005-03-10 |
| JP2007504148A (ja) | 2007-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004015810D1 (de) | Substituierte isochinolinderivate und anwendungsverfahren | |
| DE602004024900D1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
| EE200300324A (et) | Asendatud alküülamiini derivaadid ja nende kasutamismeetodid | |
| NO20060278L (no) | Piperazinderivater og fremgangsmater for anvendelse | |
| MY177111A (en) | Substituted amide derivatives and methods of use | |
| WO2004005279A3 (en) | Substituted anthranilic amide derivatives and methods of use | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| MX2009000531A (es) | Derivados heterociclicos fusionados y metodos de uso. | |
| WO2004007481A3 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders | |
| WO2002068406A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
| ATE320426T1 (de) | Harnstoffderivate und ihre verwendung | |
| TNSN06228A1 (en) | Compounds and methods of use | |
| WO2007048070A3 (en) | Pyrrolo-pyridine derivatives for the treatment of cancer diseases | |
| WO2004007457A3 (en) | Substituted benzylamine derivatives and methods of use | |
| MX2009006543A (es) | Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer. | |
| WO2007005668A3 (en) | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer | |
| WO2006041888A3 (en) | Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents | |
| MX2010004620A (es) | Derivados de benzomorfolina y metodos de uso. | |
| ATE355287T1 (de) | 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |